Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan


Last updated date
Study Location
Kushiro, Hokkaido, 085-0032, Japan


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pneumococcal DiseaseSafety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age
  1. Bristol, Tennessee
  2. Jonesboro, Arkansas
  3. Jonesboro, Arkansas
  4. Inglewood, California
  5. San Diego, California
  6. Miami, Florida
  7. Miami, Florida
  8. Chamblee, Georgia
  9. Sioux City, Iowa
  10. Newton, Kansas
  11. Wichita, Kansas
  12. Bardstown, Kentucky
  13. Lexington, Kentucky
  14. Gulfport, Mississippi
  15. Grand Island, Nebraska
  16. Lincoln, Nebraska
  17. Lincoln, Nebraska
  18. Norfolk, Nebraska
  19. Omaha, Nebraska
  20. Henderson, Nevada
  21. Albuquerque, New Mexico
  22. Binghamton, New York
  23. Dayton, Ohio
  24. Dayton, Ohio
  25. Dayton, Ohio
  26. Medford, Oregon
  27. North Charleston, South Carolina
  28. Bristol, Tennessee
  29. Austin, Texas
  30. Galveston, Texas
  31. San Antonio, Texas
  32. Murray, Utah
  33. Provo, Utah
  34. Salt Lake City, Utah
  35. Salt Lake City, Utah
  36. Salt Lake City, Utah
  37. South Jordan, Utah
  38. Syracuse, Utah
  39. Charlottesville, Virginia
  40. Charlottesville, Virginia
15 Months+
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
  1. Nedlands, Western Australia
  2. Hvidovre,
  3. Roma, Rome
  4. Stavanger,
  5. Poznan,
  6. Poznan,
  7. Westmead, New South Wales
  8. Nedlands, Western Australia
  9. Brussels,
  10. Edegem,
  11. Jindrichuv Hradec,
  12. Jindrichuv Hradec,
  13. Jindrichuv Hradec,
  14. Pardubice,
  15. Praha 3,
  16. Praha 6,
  17. Sezemice,
  18. Tallinn,
  19. Tallinn,
  20. Tallinn,
  21. Tallinn,
  22. Tartu,
  23. Espoo,
  24. Helsinki,
  25. Helsinki,
  26. Järvenpää,
  27. Kokkola,
  28. Oulu,
  29. Pori,
  30. Seinajoki,
  31. Tampere,
  32. Turku,
  33. Milano, Milan
  34. Firenze,
  35. Foggia,
  36. Genova,
  37. Haarlem,
  38. Hoofddorp,
  39. Lorenskog,
  40. Oslo,
  41. Viken,
  42. Bydgoszcz,
  43. Bydgoszcz,
  44. Debica,
  45. Krakow,
  46. Krakow,
  47. Leczna,
  48. Lodz,
  49. Lubon,
  50. Siemianowice Slaskie,
  51. Torun,
  52. Trzebnica,
  53. Warszawa,
  54. Warszawa,
  55. Wroclaw,
  56. Wroclaw,
  57. Bratislava,
  58. Bratislava,
  59. Detva,
  60. Horne Srnie,
  61. Humenne,
  62. Humenné,
  63. Kosice,
  64. Liptovská Osada,
42 Days+
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
  1. Isumi-city, Chiba
  2. Fukuoka-city, Fukuoka
  3. Fukuoka-shi, Fukuoka
  4. Osaka-City, Osaka
  5. Ritto-Shi, Shiga
  6. Nagoya-shi, Aichi
  7. Toyota-shi, Aichi
  8. Chiba-shi, Chiba
  9. Funabashi-city, Chiba
  10. Yotsukaido-shi, Chiba
  11. Yotsukaido-shi, Chiba
  12. Fukui-shi, Fukui
  13. Fukuoka-City, Fukuoka
  14. Fukuoka-city, Fukuoka
  15. Iizuka, Fukuoka
  16. Kasuga-city, Fukuoka
  17. Gifu-city, Gifu
  18. Ebetsu Shi, Hokkaido
  19. Sapporo shi, Hokkaido
  20. Sapporo, Hokkaido
  21. Akashi-City, Hyōgo
  22. Kawasaki-shi, Kanagawa
  23. Kumamoto Shi, Kumamoto
  24. Kumamoto-shi, Kumamoto
  25. Kuwana-city, MIE
  26. Nagano-shi, Nagano
  27. Kawachinagano, Osaka
  28. Ureshino-shi, Saga
  29. Hanyu-shi, Saitama
  30. Kumagaya-shi, Saitama
  31. Fuchu-city, Tokyo
  32. Nishitokyo-shi, Tokyo
  33. Setagaya-ku, Tokyo
  34. Setagaya-ku, Tokyo
  35. Shinjuku-ku, Tokyo
  36. Suginami-ku, Tokyo
  37. Kofu-city, Yamanashi
  38. Tsuru-shi, Yamanashi
2 Months+
Pneumococcal DiseaseSafety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
  1. Miami Lakes, Florida
  2. Miami, Florida
  3. Wilmington, North Carolina
  4. Oklahoma City, Oklahoma
  5. Wauwatosa, Wisconsin
  6. Birmingham, Alabama
  7. Mobile, Alabama
  8. Chandler, Arizona
  9. Phoenix, Arizona
  10. Tempe, Arizona
  11. Redding, California
  12. San Diego, California
  13. San Diego, California
  14. Walnut Creek, California
  15. Coral Gables, Florida
  16. Crystal River, Florida
  17. Hialeah, Florida
  18. Jacksonville, Florida
  19. Miami, Florida
  20. Orlando, Florida
  21. Orlando, Florida
  22. Savannah, Georgia
  23. Stockbridge, Georgia
  24. Meridian, Idaho
  25. El Dorado, Kansas
  26. Wichita, Kansas
  27. Wichita, Kansas
  28. Metairie, Louisiana
  29. New Orleans, Louisiana
  30. Elkridge, Maryland
  31. Rockville, Maryland
  32. Saint Louis, Missouri
  33. Norfolk, Nebraska
  34. Omaha, Nebraska
  35. Las Vegas, Nevada
  36. Las Vegas, Nevada
  37. Binghamton, New York
  38. Endwell, New York
  39. Charlotte, North Carolina
  40. Greensboro, North Carolina
  41. Hickory, North Carolina
  42. Raleigh, North Carolina
  43. Raleigh, North Carolina
  44. Rocky Mount, North Carolina
  45. Rocky Mount, North Carolina
  46. Fargo, North Dakota
  47. Cincinnati, Ohio
  48. Cincinnati, Ohio
  49. Cleveland, Ohio
  50. Franklin, Ohio
  51. Warwick, Rhode Island
  52. Little River, South Carolina
  53. Mount Pleasant, South Carolina
  54. Bristol, Tennessee
  55. Nashville, Tennessee
  56. Austin, Texas
  57. Cedar Park, Texas
  58. Fort Worth, Texas
  59. Fort Worth, Texas
  60. Houston, Texas
  61. McKinney, Texas
  62. Pearland, Texas
  63. San Antonio, Texas
  64. Tomball, Texas
  65. Tomball, Texas
  66. Draper, Utah
  67. Salt Lake City, Utah
  68. Salt Lake City, Utah
  69. South Jordan, Utah
  70. Norfolk, Virginia
  71. Richmond, Virginia
65 Years+
Advanced Information
Descriptive Information
Brief Title Disease Burden of Pneumonia, Meningitis and Bacteremia Among Children in Japan: Pneumonet Japan
Official Title Epidemiological Surveillance Network Study To Assess the Disease of Pneumonia in Infants and Children in Japan
Brief Summary Streptococcus pneumoniae is a major cause of pneumonia, among infants and children in Japan and worldwideThis study plans to investigate the rate of invasive pneumococcal disease "IPD " and the rate of hospitalizations due to pneumonia in Okinawa and the Eastern half of Hokkaido Currently, only a limited information about pneumococcal disease burden is available in Japan.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Infants and children less than 5 years of age living in Okinawa and Eastern Hokkaido.
Condition Pneumococcal Disease
Intervention Not Provided
Study Groups/Cohorts 1
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: March 26, 2012)
Original Estimated Enrollment
 (submitted: September 22, 2008)
Actual Study Completion Date October 2010
Actual Primary Completion Date October 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria

Eligibility Criteria

- Children residing in the surveillance area(s) aged 28 days to <60 months with clinical suspicion of pneumonia, meningitis and bacteremia who were admitted to the hospital.

Sexes Eligible for Study:All
Ages up to 60 Months   (Child)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Japan
Removed Location Countries  
Administrative Information
NCT Number NCT00757575
Other Study ID Numbers 0887X1-4424
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Study Director:Pfizer CT.gov Call CenterWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Pfizer
Verification Date March 2012